Ekstrakts na Itacen Pine Ya Rage Alamar Asarar Kashi—Amma Da Ƙalubale

Menene Masana Kimiyya Suka Gwada Da Gaske?

Karin abincin da ake magana akai shine Pycnogenol®, wani ekstrakts da aka samu daga itacen pine na teku na Faransa, wanda aka san da ƙarfinsa na anti‑oxidant da anti‑inflammatory. Har zuwa yanzu, ba a taɓa gwada tasirinsa kan rushewar ƙashi a cikin mutane ba.

Binciken (Sashi I, Frontiers in Nutrition, 2026) ya kasance gwaji mai rarrabewa bazuwar, mai ƙullun‑guda biyu, an kwatanta da placebo a cikin mata 67 da ke da osteopenia ko osteoporosis, kuma ba su sha magungunan anti‑resorptive ba a da.

• Rukunin Pycnogenol: mata 33, 100 mg sau biyu a rana (jimillar 200 mg/ranar)
• Rukunin Placebo: mata 34
• Fase 1 (watanni 3): an kwatanta da placebo
• Fase 2 (watanni 3): buɗe‑label; kowa ya ci gaba da sha Pycnogenol

Manufar farko ita ce auna alamun jini na rushewar ƙashi (CTX‑1) da na gina ƙashi (P1NP).

Gano Mai Ban Mamaki: Alamun Rushewar Kashi Sun Ragu

A rukunin Pycnogenol, matakin CTX‑1 a serum, alamar rushewar ƙashi, ya ragu sosai idan aka kwatanta da matakin da aka samu a farkon gwaji bayan watanni 3 (p = 0.0327) da kuma bayan watanni 6 (p = 0.0227). Haka kuma, alamar rushewar ƙashi ta biyu, NTX‑1, ta ragu daga matakin farko har zuwa ƙarshen fasalin buɗe‑label (p = 0.0100).

Masana sun auna wani sinadari da aka samo daga harsashin itacen pine, da ake kira M1, a cikin drobinsa. Matakan M1 sun fi na placebo a rukunin Pycnogenol bayan watanni 3 (p = 0.0289). Daga cikin samfurori 131, M1 ya nuna alaka mai ƙarfi da CTX‑1 (r = ‑0.216, p = 0.013). Gwaje‑gwajen dakin gwaje‑gwaje tare da ƙwayoyin mesenchymal na mutum sun nuna cewa sinadarai a cikin Pycnogenol na ƙara bambancin osteogenic a vitro.

Ƙalubale: Babu Bambanci Da Placebo

Duk da raguwar CTX‑1 a cikin ƙungiyar Pycnogenol, babu bambanci mai ma'ana tsakanin ƙungiyoyi a kowanne ziyara. Ragin ya faru ne idan aka kwatanta da matakin farko na ƙungiyar Pycnogenol, yayin da rukunin placebo ba su samu wani canji mai ma'ana ba. Saboda haka, raguwar da aka gani a ƙungiyar ba ta da ƙarfi sosai idan aka ɗauki placebo a matsayin ma'auni. Watakila wasu dalilai na halitta ko yanayi na rayuwa ne suka taimaka.

Alamar gina ƙashi (P1NP) ba ta canza sosai ba. Don haka, sakamakon na nuni ne da raguwar rushewar ƙashi, ba ƙara gina ƙashi ba. Marubutan sun kira wannan kariyar a matsayin potential – wato “mai yiwuwa” – ba da tabbacin karshe ba.

Fa'idojin Biyu: Ƙananan Radadi, Ƙara Ƙarfi

Takardar da ta biyo baya (Sashi II) ta duba ingancin rayuwa da aminci a cikin mata 67 da aka yi gwaji tare.

• Radadi (SF‑36v2): ya inganta a ƙungiyar Pycnogenol kuma ya wuce na placebo (p = 0.0106).
• Karfafa (Vitality): ma irin wannan fa'ida a Pycnogenol (p = 0.0282).
• Jimillar maki na QUALEFFO‑41 (ma’aunin ƙwarewar rayuwa da ke ƙunshe da osteoporosis): babu bambanci tsakanin ƙungiyoyi.
• Sashen radadi na QUALEFFO‑41: bayan watanni 6, maki sun fi ƙasa a ƙungiyar da ta ci gaba da sha Pycnogenol idan aka kwatanta da waɗanda suka canza daga placebo (p = 0.0231).

Don haka, alamar ingancin rayuwa ta nuna ci gaba a wasu fannonin, amma ba a dukkan sassa ba.

Tsarin Aminci

Lokacin gwajin, al'amuran sun kasance masu kwanciyar hankali:

• Lissafin jini, aikin kodan (GFR, urea) da alamun kumburi (CRP) ba su nuna canji mai ma'ana ba.
• Enzymen hanta AST da ALT sun zauna a matakin da ya dace.
• GGT, wani enzyme na hanta, ya nuna ƙaramar ƙasa amma mai ma'ana a rukunin da aka canza (p = 0.0141).
• Phosphate na serum ya ragu amma ya ci gaba da cikin ƙimar da ake tsammani, kuma ragin ya zama mai ma'ana bayan watanni 6 (p = 0.0039). Dole ne a kula da wannan canjin a cikin shirin ma'adanai na dogon lokaci.

Abubuwan Da Za A Iya Aiwatarwa

• Matsakaicin da aka yi amfani da shi: 100 mg Pycnogenol® sau biyu a rana, jimillar 200 mg/ranar. Takardun ba su ba da umarnin cin abinci ba, don haka ba a fayyace wani “lokaci mafi kyau” ba.
• Tsawon gwaji: watanni 3 na placebo, sannan watanni 3 na buɗe‑label. Babu bayanai bayan watanni 6.
• Masu amfani da zai iya amfana: mata da ke da osteopenia ko osteoporosis, waɗanda ba su riga sun fara magungunan anti‑resorptive ba – a matsayin bincike na farko.
• Wanda ya kamata ya yi taka tsantsan ko guje wa:
  • Duk wanda ke tunanin zai maye gurbin magungunan osteoporosis da aka rubuta. Marubutan sun jaddada cewa anti‑resorptives sune ƙa’ida mafi kyau, wannan gwaji yana nuna ƙarin kari, ba maye gurbi ba.
  • Maza, yara ko matasa, da kuma mata da ke da cututtuka masu tsanani da ba su shiga cikin wannan bincike ba.
  • Mutane masu matsalar hanta, kodan ko ma'adanai, ko masu shan wasu magunguna. Takardun ba su tattauna haɗin kai ba, don haka a tuntuɓi likita kafin farawa.

Iyakoki Da Ya Kamata Ka Sani

• Samfurin ƙanana: mata 67 da lokaci ba daɗewa na watanni 6 kawai.
• Manufofi na wakilci: alamar rushewar ƙashi ba su wakilci fashe‑fashe ko ƙimar ƙashi ba, kuma babu takardar da ta ba da irin waɗannan sakamakon.
• Babu bambanci a CTX‑1 tsakanin ƙungiyoyi kuma ba a sami canji a P1NP ba.
• Buɗe‑label extension: kowa ya sha Pycnogenol daga watanni 4 zuwa 6, don haka sakamakon ba shi da ma'aunin placebo a wannan mataki.
• Yawancin p‑values suna da ƙima kaɗan, don haka fassara da hankali ya zama tilas.
• Alakar M1 ba ta da ƙarfi, kuma sakamakon in vitro ba su tabbatar da irin tasirin da ake samu a jiki.

Marubutan sun bayyana babu wani rikici na kasuwanci ko na kuɗi, kuma an yi rijistar gwajin (DRKS00026630).

Gabaɗaya

Wannan gwaji yana ba da alƙawari na farko, ba hujja mai ƙarfi ba. Ekstrakts na itacen pine ya nuna raguwar alamar rushewar ƙashi, ƙananan radadi, da ƙara ƙarfi, tare da tsayayyen tsarin aminci na ɗan gajeren lokaci. Tambayar ita ce ko wannan zai haifar da ƙashi mafi ƙarfi ko rage fashe‑fashe a nan gaba – abin da gwaje‑gwaje masu tsawo da suka haɗa da ƙimar ƙashi da faruwar fashe‑fashe za su fayyace.